EN DE
Watch Qing Song Health Co.,Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Qing Song Health Co.,Ltd. (6931) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Qing Song Health Co.,Ltd. stock TWD 21.01, price TWD 36.40, that is 42.3% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

QS Qing Song Health Co.,Ltd. logo Broad data Nov 9, 2026

Qing Song Health Co.,Ltd.

6931 · TW
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Highly profitable · 20.6% net margin (TTM)
Low debt
Broad data
Revenue last quarter +15% vs. a year ago.
Expensive Growth (revenue 3y +20.8 %/yr in TWD)
0.3% dividend yield · Token dividend
Moderate moat 53/100 · thin data
Fair value 21.01 TWD · Strongly overvalued
Quality 39/100
Negative free cash flow
Trails peers (5/13)
Watch Qing Song Health Co.,Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

107.50 TWD 31.93 TWD Fair Value 21.01 TWD Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

46‑month range 31.93 TWD – 107.50 TWD · fair‑value band 12.84 TWD – 34.92 TWD · the 36.40 TWD price screens above the 21.01 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Qing Song Health Co. in your weekly email

Every Wednesday you see whether Qing Song Health Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Qing Song Health Co.,Ltd. provides long-term care services in Taiwan. It offers community-based and residential long-term care services, providing home, and community to residential and other diversified care. The company was founded in 1996 and is based in Taichung, Taiwan.

Stock analysis

Qing Song Health Co.,Ltd. (6931) currently trades at 36.40 TWD, while our model-based Fair Value estimate is 21.01 TWD, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 39.67 TWD per share, and 4 of the 17 models we run sit above the 36.40 TWD price.

Bear case: the Dividend Discount group reads lowest at 6.32 TWD, and 13 of the 17 models stay below the price. Data coverage for this calculation is high.

Scenario range: 12.84 TWD (bear) to 34.92 TWD (bull), the price of 36.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Qing Song Health Co.,Ltd. reported revenue of 1.1B TWD in FY2025 versus 358M TWD in FY2021, a compound +33.1%/yr. Reported net income was 91.7M TWD in FY2025.

Key figures

Market cap 2.4B TWD (≈ $73.3M) Micro · P/E ratio 9.7 · P/S ratio 1.99 · EPS (TTM) 3.76 TWD · Dividend yield 0.3% · Net margin 20.6% · Return on equity 21.3% · Return on assets (EBIT) 1.7% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −42%, 6931 screens richer than that median.

Fair Value models

Bear 12.84 TWD Fair Value 21.01 TWD Bull 34.92 TWD
Price 36.40 TWD · Downside -42.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.12 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 12.71 TWD 13.03 TWD 14.06 TWD 73
Owner Earnings 12.84 TWD 21.01 TWD 34.92 TWD 71
EPV 8.63 TWD 9.16 TWD 9.59 TWD 71
All 17 models by family
DCF Models
Owner Earnings 12.84 TWD 21.01 TWD 34.92 TWD 71
Earnings-Based
Graham-Dodd 9.43 TWD 65.74 TWD 92.26 TWD 60
Lynch FV 20.12 TWD 28.74 TWD 37.36 TWD 58
PEG = 1.0 20.12 TWD 28.74 TWD 37.36 TWD 55
EPV 8.63 TWD 9.16 TWD 9.59 TWD 71
Dividend Discount
Gordon GGM 3.97 TWD 6.44 TWD 8.17 TWD 66
DDM Multi-Stage 3.97 TWD 6.20 TWD 6.95 TWD 65
Multiples
P/E Multiple 22.87 TWD 30.50 TWD 38.12 TWD 63
P/S Multiple 17.67 TWD 23.57 TWD 29.46 TWD 58
P/B Multiple 58.36 TWD 77.81 TWD 97.26 TWD 55
EV/EBIT 15.15 TWD 18.89 TWD 22.63 TWD 66
EV/EBITDA 35.74 TWD 46.35 TWD 56.95 TWD 67
EV/Revenue 11.94 TWD 15.37 TWD 18.80 TWD 54
Asset-Based
NCAV (Graham) 8.65 TWD 11.59 TWD 17.29 TWD 54
Economic Profit
Residual Income 12.71 TWD 13.03 TWD 14.06 TWD 73
ROIC Compounder 8.63 TWD 9.16 TWD 9.59 TWD 69
Growth Earnings
Growth-Adj P/E 27.77 TWD 39.67 TWD 51.57 TWD 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 30
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 26
Does it invest with discipline instead of growing at any price?
Low Volatility 82
How calm the share price moves, does not count
Price momentum 24
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
What shareholders gained per year (last 3 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +16.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+15.7%
Dividend (yield on the price)0.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 5%
⚠ Rate on operating basis: 2025 sits 105% above its own trend.

6931 screens overvalued: fair value 42% below the price. Compare with HCA Healthcare, Inc →

Compare Qing Song Health Co.,Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside −42.3% · Bottom 25%
Profitability
Return on equity (12 months) 21.3% · Top 25%
Return on assets 3.6% · Below median
Net margin (12 months) 20.6% · Top 25%
Operating margin (12 months) 7.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.4% · Top 25%
Dividend yield (12 months) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 9.7× · Cheapest 25%
P/B 2.11× · Pricier than median
P/S (12 months) 1.99× · Pricier than median
EV/EBITDA 13.9× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)77 · sector 31
PAST (return on equity)85 · sector 33
HEALTH (low debt)94 · sector 90
DIVIDEND (yield)7 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs 6931
Aier Eye Hospital Group 300015 ¥8.93 ¥10.88 +22% vs 6931
DaVita Inc DVA $191.35 $218.90 +14% vs 6931
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs 6931
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs 6931
The Ensign Group ENSG $181.08 $140.09 −23% vs 6931
Encompass Health Corporation EHC $137.54 $94.81 −31% vs 6931
Fresenius SE FRE €52.46 €34.77 −34% vs 6931
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,550 ₹5,234 −39% vs 6931
Dr. Sulaiman Al Habib Medical Services Group 4013 214.20 SAR 109.45 SAR −49% vs 6931

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Qing Song Health Co.,Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Qing Song Health Co.,Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6931

Frequently asked questions

Is Qing Song Health Co.,Ltd. (6931) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 21.01 TWD versus a price of 36.40 TWD, about 42% lower (overvalued).
What is the fair value of 6931?
Our model-based fair value for Qing Song Health Co.,Ltd. is 21.01 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 36.40 TWD.
What is the quality score of 6931?
Qing Song Health Co.,Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qing Song Health Co.,Ltd. (6931)?
Our model-based price target is the fair value of 21.01 TWD (as of Nov 9, 2026) from 17 valuation models. Cautious scenario 12.84 TWD, optimistic scenario 34.92 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Qing Song Health Co.,Ltd. stock forecast for 2026?
Our models put fair value at 21.01 TWD, about 42% lower versus a price of 36.40 TWD (overvalued). Cautious scenario 12.84 TWD, optimistic scenario 34.92 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Qing Song Health Co.,Ltd. (6931)?
Qing Song Health Co.,Ltd. reported trailing-twelve-month revenue of about 1.2B TWD (latest available figure, as of Nov 9, 2026).
Does Qing Song Health Co.,Ltd. pay a dividend?
Qing Song Health Co.,Ltd. currently shows a dividend yield of 0.33% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Qing Song Health Co.,Ltd. (6931) and when is the ex-dividend date?
Qing Song Health Co.,Ltd. pays a dividend of 0.12 TWD per share a year, a dividend yield of 0.3%. The last ex-dividend date was Oct 27, 2026. The payout ratio is 3.2% of earnings. Our assessment: Token dividend. At a yield of 0.3% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.3% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Qing Song Health Co.,Ltd. (6931)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qing Song Health Co.,Ltd. it is 21.01 TWD per share (as of Nov 9, 2026), against a price of 36.40 TWD. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Qing Song Health Co.,Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6931 trades above its calculated fair value: price 36.40 TWD, fair value 21.01 TWD, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6931?
No. The price is what the market pays today (36.40 TWD); the fair value is what the company's own numbers justify (21.01 TWD). For Qing Song Health Co.,Ltd. the two are 15.39 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Qing Song Health Co.,Ltd. worth?
The market values Qing Song Health Co.,Ltd. at about 2.4B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 36.40 TWD; our models calculate a fair value of 21.01 TWD per share.
What do the bullish and bearish scenarios say about 6931?
Our models span a range for Qing Song Health Co.,Ltd.: cautious scenario 12.84 TWD, base 21.01 TWD, optimistic 34.92 TWD per share (as of Nov 9, 2026, price 36.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6931?
Qing Song Health Co.,Ltd. trades at a price-to-earnings ratio of 9.7 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 21.01 TWD is built from several models across several years. Other multiples: P/B 2.1, P/S 2.0, EV/EBITDA 13.9.
How solid is the balance sheet of Qing Song Health Co.,Ltd. (6931)?
Balance-sheet figures for Qing Song Health Co.,Ltd. (as of Nov 9, 2026): return on equity 21.3%, debt of 0.12 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 6931 from its 52-week high?
Qing Song Health Co.,Ltd. trades at 36.40 TWD, about 46% below its 52-week high of 67.43 TWD and 1% above the low of 36.09 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 21.01 TWD is for.
Which stocks are comparable to Qing Song Health Co.,Ltd.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qing Song Health Co.,Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 36.40 TWD, calculated fair value 21.01 TWD (−42%), Quality Score 39/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6931 calculated?
We run Qing Song Health Co.,Ltd. through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 21.01 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Qing Song Health Co.,Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qing Song Health Co.,Ltd. (6931)?
The closing price on Nov 9, 2026 was 36.40 TWD. Our model-based fair value is 21.01 TWD, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qing Song Health Co.,Ltd. right now?
The price sits above even our optimistic bull case (34.92 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (12.84 TWD to 34.92 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Qing Song Health Co.,Ltd.

How large is the market capitalisation of Qing Song Health Co.,Ltd. (6931)?
The market capitalisation of Qing Song Health Co.,Ltd. is 2.4B TWD (≈ $73.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qing Song Health Co.,Ltd. (6931)?
The price-to-sales ratio of Qing Song Health Co.,Ltd. is 1.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qing Song Health Co.,Ltd. (6931)?
Earnings per share at Qing Song Health Co.,Ltd. are 3.76 TWD (price ÷ EPS = P/E 9.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Qing Song Health Co.,Ltd. (6931)?
The dividend yield of Qing Song Health Co.,Ltd. is 0.3% (payout 3.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Qing Song Health Co.,Ltd. (6931)?
The net margin of Qing Song Health Co.,Ltd. is 20.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qing Song Health Co.,Ltd. (6931)?
The return on equity (ROE) of Qing Song Health Co.,Ltd. is 21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qing Song Health Co.,Ltd. (6931)?
On an EBIT basis the return on assets of Qing Song Health Co.,Ltd. is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qing Song Health Co.,Ltd. (6931)?
The operating margin of Qing Song Health Co.,Ltd. is 7.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qing Song Health Co.,Ltd. (6931)?
Revenue at Qing Song Health Co.,Ltd. is growing +15.4% versus a year earlier (3y avg +20.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Qing Song Health Co.,Ltd. (6931)?
Earnings per share at Qing Song Health Co.,Ltd. are growing +508% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Qing Song Health Co.,Ltd. (6931) generate?
The free cash flow of Qing Song Health Co.,Ltd. is −152M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Qing Song Health Co.,Ltd. in the live analysis

One click puts Qing Song Health Co.,Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.